Literature DB >> 16504663

Possible association of cytotoxic T-lymphocyte antigen 4 gene promoter single nucleotide polymorphism with acute rejection of allogeneic kidney transplant.

A Wiśniewski1, M Kusztal, M Magott-Procelewska, M Klinger, M Jasek, W Łuszczek, I Nowak, A Kosmaczewska, L Ciszak, I Frydecka, A Górski, P Kuśnierczyk.   

Abstract

Cytotoxic T-lymphocyte antigen 4 (CTLA-4) molecule is an important inhibitor of T-lymphocyte response. Polymorphisms in the CTLA-4 gene have been described to be associated with numerous autoimmune diseases. However, similar studies in solid organ transplantation have been scarce. Therefore, we examined the distribution of three single nucleotide dimorphisms, namely, -1147T/C, -318C/T, and +49A/G, in two groups of allogeneic kidney graft recipients: (1) those with at least one acute rejection episode ("rejectors"; n = 38) and (2) those with no signs of acute rejection ("nonrejectors"; n = 53). Allele frequencies in both groups of patients were similar in two positions, -1147T/C and +49A/G. However, rejectors showed slight differences from nonrejectors for allele and genotype frequencies in position -318. The -318T allele was two times less frequent among rejectors than nonrejectors, a difference that was close to statistical significance (P = .039; P corrected = .0583), and may reach it when greater numbers of patients are tested.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16504663     DOI: 10.1016/j.transproceed.2005.11.094

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  8 in total

1.  Polymorphisms in the cytotoxic T-lymphocyte antigen 4 gene and acute rejection risk in transplant recipients.

Authors:  Cheng-Lin Zhu; Qiang Huang; Chen-Hai Liu; Fang Xie
Journal:  Mol Biol Rep       Date:  2012-06-19       Impact factor: 2.316

2.  Influence of cytotoxic T lymphocyte antigen 4 genetic variants on acute rejection in kidney transplant patients: precision medicine perspective.

Authors:  Andia Taleb; Mahdi Afshari; Mohammad Samzadeh; Negar Sarhangi; Mohsen Nafar; Mandana Hasanzad
Journal:  J Diabetes Metab Disord       Date:  2021-12-02

Review 3.  Immune tolerance induction by integrating innate and adaptive immune regulators.

Authors:  Jun Suzuki; Camillo Ricordi; Zhibin Chen
Journal:  Cell Transplant       Date:  2009-11-16       Impact factor: 4.064

4.  A CT60G>A polymorphism in the CTLA-4 gene of the recipient may confer susceptibility to acute graft versus host disease after allogeneic hematopoietic stem cell transplantation.

Authors:  Lidia Karabon; Miroslaw Markiewicz; Anna Partyka; Edyta Pawlak-Adamska; Anna Tomkiewicz; Monika Dzierzak-Mietla; Slawomira Kyrcz-Krzemien; Irena Frydecka
Journal:  Immunogenetics       Date:  2015-05-05       Impact factor: 2.846

5.  Effect of CTLA-4 gene polymorphisms on long-term kidney allograft function in Han Chinese recipients.

Authors:  Yifeng Guo; Junwei Gao; Shuai Gao; Minghua Shang; Fang Guo
Journal:  Oncotarget       Date:  2016-04-26

6.  The Influence of Genetic Variations in the CD86 Gene on the Outcome after Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Lidia Karabon; Miroslaw Markiewicz; Karolina Chrobot; Monika Dzierzak-Mietla; Edyta Pawlak-Adamska; Anna Partyka; Anna Koclega; Slawomira Kyrcz-Krzemien; Irena Frydecka
Journal:  J Immunol Res       Date:  2018-02-07       Impact factor: 4.818

7.  Association of Polymorphisms in T-Cell Activation Costimulatory/Inhibitory Signal Genes With Allograft Kidney Rejection Risk.

Authors:  Jose Luis Santiago; Luis Sánchez-Pérez; Isabel Pérez-Flores; Maria Angeles Moreno de la Higuera; Natividad Calvo Romero; Javier Querol-García; Elena Urcelay; Ana Isabel Sánchez-Fructuoso
Journal:  Front Immunol       Date:  2021-06-02       Impact factor: 7.561

8.  CTLA-4 rs231775 and risk of acute renal graft rejection: an updated meta-analysis with trial sequential analysis.

Authors:  Sarah Cargnin; Ubaldina Galli; Jae Il Shin; Salvatore Terrazzino
Journal:  Sci Rep       Date:  2020-07-30       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.